Background Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has been co-
formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate …

BACKGROUND: The rising prevalence and associated public health burden of obesity has
led to advancements in pharmaceuticals for weight management. Semaglutide 2.4 mg, an …

Aim To assess the efficacy and safety of oral semaglutide, a novel glucagon‐like peptide‐1
receptor agonist, for patients with type 2 diabetes. Methods We searched Medline, Embase …

1 BACKGROUND Type 2 diabetes guidelines recommend glucagon-like peptide-1 receptor
agonists (GLP-1 RAs) and/or sodium-glucose co-transporter-2 inhibitors for people living …

Aims To assess the safety and efficacy of monotherapy with once‐weekly subcutaneous (sc)
semaglutide vs sitagliptin in Japanese people with type 2 diabetes (T2D). Methods In this …

Objective: To detail studies investigating the efficacy/safety of semaglutide as a glucagon-
like peptide-1 receptor agonist (GLP-1 RA) in the treatment of type 2 diabetes mellitus. Data …

Objective To review the pharmacology, efficacy, and safety of high-dose once-weekly
semaglutide for chronic weight management. Data Sources PubMed/MEDLINE and …

Aims Real‐world data are required to support glucagon‐like peptide‐1 receptor agonist use
in type 2 diabetes (T2D). SURE France assessed once‐weekly semaglutide in adults with …

Background and aim The importance of glucagon-like peptide-1 (GLP-1) agonists is
increasing because of its blood sugar controlling and weight loss properties. The data …

The prevalence of obesity and related comorbidities is increasing worldwide. Furthermore,
clinically meaningful body weight losses has proven difficult to achieve and especially to …